You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEszopiclone
Accession NumberDB00402  (APRD00431)
TypeSmall Molecule
GroupsApproved
DescriptionEszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic agent (viz., a sedative) used as a treatment for insomnia. Eszopiclone is the active stereoisomer of zopiclone, and belongs to the class of drugs known as cyclopyrrones. Its main selling point is that it is approved by the U.S. Food and Drug Administration for long-term use, unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia.
Structure
Thumb
Synonyms
(+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate
(+)-(5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl-4-methylpiperazine-1-carboxylate
(+)-Zopiclone
(S)-6-(5-Chloro-2-pyridinyl)- 7-oxo- 6,7-dihydro- 5H-pyrrolo[3,4-b]pyrazin-5-yl- 4-methyl- 1-piperazinecarboxylate
(S)-Zopiclone
1-Piperazinecarobxylic acid,4-methyl-,(5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester
Esopiclone
Estorra
Eszopiclone
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Lunestatablet, coated3 mg/1oralUnit Dose Services2005-04-04Not applicableUs
Lunestatablet, coated2 mg/1oralbryant ranch prepack2005-04-04Not applicableUs
Lunestatablet, coated2 mg/1oralRebel Distributors Corp2009-01-01Not applicableUs
Lunestatablet, coated3 mg/1oralPd Rx Pharmaceuticals, Inc.2005-04-04Not applicableUs
Lunestatablet, coated2 mg/1oralA S Medication Solutions Llc2005-04-04Not applicableUs
Lunestatablet2 mgoralSunovion Pharmaceuticals Canada IncNot applicableNot applicableCanada
Lunestatablet, coated2 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-18Not applicableUs
Lunestatablet, coated2 mg/1oralSunovion Pharmaceuticals Inc.2005-04-04Not applicableUs
Lunestatablet, coated3 mg/1oralH.J. Harkins Company, Inc.2005-04-04Not applicableUs
Lunestatablet, coated2 mg/1oralDispensing Solutions, Inc.2005-04-04Not applicableUs
Lunestatablet, coated3 mg/1oralRebel Distributors Corp2009-01-01Not applicableUs
Lunestatablet, coated2 mg/1oralSt Marys Medical Park Pharmacy2005-04-04Not applicableUs
Lunestatablet, coated2 mg/1oralPhysicians Total Care, Inc.2005-04-27Not applicableUs
Lunestatablet3 mgoralSunovion Pharmaceuticals Canada IncNot applicableNot applicableCanada
Lunestatablet, coated3 mg/1oralA S Medication Solutions Llc2005-04-04Not applicableUs
Lunestatablet, coated3 mg/1oralSunovion Pharmaceuticals Inc.2005-04-04Not applicableUs
Lunestatablet, coated2 mg/1oralH.J. Harkins Company, Inc.2005-04-04Not applicableUs
Lunestatablet, coated3 mg/1oralDispensing Solutions, Inc.2005-04-04Not applicableUs
Lunestatablet, coated3 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-07-18Not applicableUs
Lunestatablet, coated3 mg/1oralSt Marys Medical Park Pharmacy2005-04-04Not applicableUs
Lunestatablet, coated3 mg/1oralPhysicians Total Care, Inc.2005-08-24Not applicableUs
Lunestatablet, coated2 mg/1oralA S Medication Solutions Llc2005-04-04Not applicableUs
Lunestatablet, coated3 mg/1oralbryant ranch prepack2005-04-04Not applicableUs
Lunestatablet, coated3 mg/1oralA S Medication Solutions Llc2005-04-04Not applicableUs
Lunestatablet1 mgoralSunovion Pharmaceuticals Canada IncNot applicableNot applicableCanada
Lunestatablet, coated1 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-07-18Not applicableUs
Lunestatablet, coated1 mg/1oralSunovion Pharmaceuticals Inc.2005-04-04Not applicableUs
Lunestatablet, coated1 mg/1oralPhysicians Total Care, Inc.2006-09-29Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Eszopiclonetablet, film coated2 mg/1oralMylan Pharmaceuticals Inc.2013-03-26Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralSun Pharma Global FZE2014-04-15Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralDIRECT RX2014-01-01Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralPreferred Pharmaceuticals Inc.2015-10-06Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralGolden State Medical Supply, Inc.2016-01-19Not applicableUs
Eszopiclonetablet1 mg/1oralRoxane Laboratories, Inc.2014-04-15Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralAv Kare, Inc.2014-05-15Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralMylan Institutional Inc.2014-11-11Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralbryant ranch prepack2014-04-15Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralPreferred Pharmaceuticals, Inc.2014-04-15Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-15Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralMacleods Pharmaceuticals Limited2014-04-25Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralUnit Dose Services2014-04-15Not applicableUs
Eszopiclonetablet2 mg/1oralProficient Rx LP2014-04-15Not applicableUs
Eszopiclonetablet, coated2 mg/1oralDr. Reddy's Laboratories Limited2014-04-15Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralGlenmark Pharmaceuticals Inc., Usa2014-04-15Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralA S Medication Solutions2014-04-14Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralTeva Pharmaceuticals USA Inc2014-04-14Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralMedsource Pharmaceuticals2014-04-15Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralMylan Pharmaceuticals Inc.2013-03-26Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralSun Pharma Global FZE2014-04-15Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralDIRECT RX2015-01-01Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralPreferred Pharmaceuticals Inc.2015-11-20Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralSt. Mary's Medical Park Pharmacy2016-04-14Not applicableUs
Eszopiclonetablet2 mg/1oralRoxane Laboratories, Inc.2014-04-15Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralAv Kare, Inc.2014-05-15Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralA S Medication Solutions Llc2014-04-15Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralLupin Pharmaceuticals, Inc.2014-04-15Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralA S Medication Solutions2014-04-15Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralProficient Rx LP2014-09-25Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-15Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralOrchid Pharma Inc2014-09-25Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralUnit Dose Services2014-04-14Not applicableUs
Eszopiclonetablet, coated1 mg/1oralDr. Reddy's Laboratories Limited2014-04-15Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralGlenmark Pharmaceuticals Inc., Usa2014-04-15Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralGolden State Medical Supply, Inc.2016-01-19Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralTeva Pharmaceuticals USA Inc2014-04-14Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralMedsource Pharmaceuticals2014-04-15Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralMacleods Pharmaceuticals Limited2014-04-25Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralA S Medication Solutions Llc2014-04-15Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralDIRECT RX2015-12-01Not applicableUs
Eszopiclonetablet3 mg/1oralPreferred Pharmaceuticals, Inc.2014-10-13Not applicableUs
Eszopiclonetablet3 mg/1oralRoxane Laboratories, Inc.2014-04-15Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralAv Kare, Inc.2014-05-15Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralA S Medication Solutions Llc2014-04-15Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralLupin Pharmaceuticals, Inc.2014-04-15Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralDIRECT RX2015-12-15Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralbryant ranch prepack2014-04-15Not applicableUs
Eszopiclonetablet1 mg/1oralPreferred Pharmaceuticals, Inc.2014-10-20Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralOrchid Pharma Inc2014-09-25Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralUnit Dose Services2014-04-14Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralDIRECT RX2015-01-01Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralGlenmark Pharmaceuticals Inc., Usa2014-04-15Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralGolden State Medical Supply, Inc.2016-01-19Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralMylan Pharmaceuticals Inc.2013-03-26Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralSun Pharma Global FZE2014-04-15Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralMacleods Pharmaceuticals Limited2014-04-25Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralA S Medication Solutions Llc2014-04-15Not applicableUs
Eszopiclonetablet1 mg/1oralProficient Rx LP2014-04-15Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-21Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralProficient Rx LP2014-09-25Not applicableUs
Eszopiclonetablet, film coated1 mg/1oralTeva Pharmaceuticals USA Inc2014-04-14Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralMedsource Pharmaceuticals2014-04-15Not applicableUs
Eszopiclonetablet, coated3 mg/1oralDr. Reddy's Laboratories Limited2014-04-15Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralLupin Pharmaceuticals, Inc.2014-04-15Not applicableUs
Eszopiclonetablet, film coated2 mg/1oralMylan Institutional Inc.2014-11-11Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralbryant ranch prepack2014-04-15Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralPreferred Pharmaceuticals Inc.2015-08-18Not applicableUs
Eszopiclonetablet, film coated3 mg/1oralOrchid Pharma Inc2014-09-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DorplenLKM
EsleepOpsonin
EszopSilesia
FulniteSun
InductalRoemmers
IsoklonTecnoquimicas
NirvanSaval
NopticAndromaco
PlessirMedipharm
SanilentSanitas
SleepilAristopharma
SonoAcme
ValnocDrugtech
Wen FeiTasly
ZopiloneIncepta
ZopinonChile
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIUZX80K71OE
CAS number138729-47-2
WeightAverage: 388.808
Monoisotopic: 388.105066147
Chemical FormulaC17H17ClN6O3
InChI KeyInChIKey=GBBSUAFBMRNDJC-INIZCTEOSA-N
InChI
InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1
IUPAC Name
(5S)-6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate
SMILES
CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cyclopyrrolones. These are compounds belonging to a family of pyridin-2-ylpyrrole based chemicals. The pyrrole is usually fused to a benzene, pyrimidine, or dithiin.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyrrolopyrazines
Sub ClassCyclopyrrolones
Direct ParentCyclopyrrolones
Alternative Parents
Substituents
  • Cyclopyrrolone
  • Piperazine-1-carboxylic acid
  • N-alkylpiperazine
  • N-methylpiperazine
  • Aminopyridine
  • Imidolactam
  • Pyridine
  • Pyrazine
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of insomnia
PharmacodynamicsEszopiclone is a nonbenzodiazepine hypnotic, pyrrolopyrazine derivative of the cyclopyrrolone class and is indicated for the short-term treatment of insomnia. While Eszopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Eszopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor.
Mechanism of actionThe mechanism of action of Eszopiclone is not completely understood. It is thought that Eszopiclone acts on the benzodiazepine receptors as an agonist and interacts with GABA-receptor complexes.
Related Articles
AbsorptionRapidly absorbed following oral administration
Volume of distributionNot Available
Protein binding52-59%
Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation.

SubstrateEnzymesProduct
Eszopiclone
Zopiclone N-oxideDetails
Eszopiclone
nopiclone N-oxideDetails
Eszopiclone
zopiclone-N-oxideDetails
Eszopiclone
N-desmethylzopicloneDetails
Eszopiclone
Carbon dioxideDetails
Route of eliminationUp to 75% of an oral dose of racemic zopiclone is excreted in the urine, primarily as metabolites.
Half life6 hours
ClearanceNot Available
ToxicitySide effects include viral infection, dry mouth, dizziness, hallucinations, infection, rash, and unpleasant taste, with this relationship clearest for unpleasant taste depending on doses.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9382
Caco-2 permeable+0.5805
P-glycoprotein substrateSubstrate0.6917
P-glycoprotein inhibitor IInhibitor0.6381
P-glycoprotein inhibitor IIInhibitor0.5
Renal organic cation transporterNon-inhibitor0.6785
CYP450 2C9 substrateNon-substrate0.7158
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.6775
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorInhibitor0.8995
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.689
Ames testAMES toxic0.5332
CarcinogenicityNon-carcinogens0.9174
BiodegradationNot ready biodegradable0.9941
Rat acute toxicity2.6411 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7838
hERG inhibition (predictor II)Non-inhibitor0.5688
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sepracor inc
  • Sepracor Inc.
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 mg/1
Tabletoral2 mg/1
Tabletoral3 mg/1
Tablet, film coatedoral1 mg/1
Tablet, film coatedoral2 mg/1
Tablet, film coatedoral3 mg/1
Tabletoral1 mg
Tabletoral2 mg
Tabletoral3 mg
Tablet, coatedoral1 mg/1
Tablet, coatedoral2 mg/1
Tablet, coatedoral3 mg/1
Prices
Unit descriptionCostUnit
Lunesta 2 mg tablet8.08USD tablet
Lunesta 3 mg tablet7.28USD tablet
Lunesta 1 mg tablet7.24USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6319926 No1995-01-162012-01-16Us
US6444673 No1994-02-142014-02-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityvery slightly solubleNot Available
logP0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.885 mg/mLALOGPS
logP0.97ALOGPS
logP0.81ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)13.04ChemAxon
pKa (Strongest Basic)6.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area91.76 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity95.89 m3·mol-1ChemAxon
Polarizability37.67 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Marioara MENDELOVICI, Anita LIBERMAN, Alex MAINFELD, Nina FINKELSTEIN, “METHODS FOR PREPARING ESZOPICLONE CRYSTALLINE FORM A, SUBSTANTIALLY PURE ESZOPICLONE AND OPTICALLY ENRICHED ESZOPICLONE.” U.S. Patent US20070270590, issued November 22, 2007.

US20070270590
General ReferencesNot Available
External Links
ATC CodesN05CF04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (252 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Eszopiclone is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Eszopiclone can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Eszopiclone is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Alprazolam.
AmiodaroneThe metabolism of Eszopiclone can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amperozide.
AprepitantThe serum concentration of Eszopiclone can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Asenapine.
AtazanavirThe metabolism of Eszopiclone can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Eszopiclone can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Azaperone.
AzelastineEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Eszopiclone.
BaclofenThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Eszopiclone can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Eszopiclone can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Eszopiclone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Eszopiclone can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
BrimonidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Eszopiclone.
BuprenorphineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Eszopiclone.
ButacaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butorphanol.
CapecitabineThe metabolism of Eszopiclone can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carisoprodol.
CelecoxibThe metabolism of Eszopiclone can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Eszopiclone can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Eszopiclone can be decreased when combined with Cholecalciferol.
CinchocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Citalopram.
ClarithromycinThe metabolism of Eszopiclone can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Eszopiclone can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Eszopiclone is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clonidine.
ClopidogrelThe metabolism of Eszopiclone can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clorazepate.
ClotrimazoleThe metabolism of Eszopiclone can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Eszopiclone.
CobicistatThe metabolism of Eszopiclone can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Eszopiclone.
ConivaptanThe serum concentration of Eszopiclone can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Eszopiclone can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Eszopiclone can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyproheptadine.
DabrafenibThe serum concentration of Eszopiclone can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Eszopiclone.
DapoxetineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dapoxetine.
DarunavirThe metabolism of Eszopiclone can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Eszopiclone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Eszopiclone can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Eszopiclone can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Detomidine.
DexamethasoneThe serum concentration of Eszopiclone can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Eszopiclone can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydromorphine.
DiltiazemThe metabolism of Eszopiclone can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Doxepin.
DoxycyclineThe metabolism of Eszopiclone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
DoxylamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Eszopiclone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
DronedaroneThe metabolism of Eszopiclone can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Eszopiclone is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Eszopiclone can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Eszopiclone.
EntacaponeThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Entacapone.
EnzalutamideThe serum concentration of Eszopiclone can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Eszopiclone can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Eszopiclone can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Estazolam.
EthanolEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Eszopiclone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eszopiclone.
EthosuximideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Eszopiclone.
EtoperidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etorphine.
EtravirineThe serum concentration of Eszopiclone can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Felbamate.
FelodipineThe metabolism of Eszopiclone can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flibanserin.
FloxuridineThe metabolism of Eszopiclone can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Eszopiclone can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fludiazepam.
FlumazenilFlumazenil may decrease the sedative activities of Eszopiclone.
FlunarizineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flunitrazepam.
FluorouracilThe metabolism of Eszopiclone can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Eszopiclone can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluvoxamine.
FluvoxamineThe metabolism of Eszopiclone can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Eszopiclone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Eszopiclone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fospropofol.
Fusidic AcidThe serum concentration of Eszopiclone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Eszopiclone is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Eszopiclone can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Eszopiclone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
HydroxyzineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Hydroxyzine.
IdelalisibThe serum concentration of Eszopiclone can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Iloperidone.
ImatinibThe metabolism of Eszopiclone can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Indalpine.
IndinavirThe metabolism of Eszopiclone can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Eszopiclone can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Eszopiclone can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Isoflurane.
IsradipineThe metabolism of Eszopiclone can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Eszopiclone can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Eszopiclone can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketobemidone.
KetoconazoleThe metabolism of Eszopiclone can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lamotrigine.
LapatinibThe metabolism of Eszopiclone can be decreased when combined with Lapatinib.
LeflunomideThe metabolism of Eszopiclone can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Eszopiclone.
LithiumThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lofentanil.
LopinavirThe metabolism of Eszopiclone can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Eszopiclone.
LosartanThe metabolism of Eszopiclone can be decreased when combined with Losartan.
LovastatinThe metabolism of Eszopiclone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Eszopiclone is combined with Lu AA21004.
LuliconazoleThe serum concentration of Eszopiclone can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Eszopiclone can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Eszopiclone.
MesoridazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Eszopiclone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methylphenobarbital.
MetyrosineEszopiclone may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Midazolam.
MifepristoneThe metabolism of Eszopiclone can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
MirtazapineEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Eszopiclone.
MitotaneThe serum concentration of Eszopiclone can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Eszopiclone can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Eszopiclone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
NabiloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nabilone.
NafcillinThe serum concentration of Eszopiclone can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nalbuphine.
NefazodoneThe metabolism of Eszopiclone can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Eszopiclone can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Eszopiclone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Eszopiclone can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Eszopiclone can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Eszopiclone can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Olanzapine.
OlaparibThe metabolism of Eszopiclone can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Olopatadine.
OmeprazoleThe metabolism of Eszopiclone can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Opium.
OrphenadrineEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Eszopiclone.
OsanetantThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Osanetant.
OsimertinibThe serum concentration of Eszopiclone can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxymorphone.
PalbociclibThe serum concentration of Eszopiclone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paliperidone.
ParaldehydeEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Eszopiclone.
ParoxetineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Eszopiclone.
PerampanelThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pethidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pimozide.
PioglitazoneThe metabolism of Eszopiclone can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pomalidomide.
PosaconazoleThe metabolism of Eszopiclone can be decreased when combined with Posaconazole.
PramipexoleEszopiclone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Eszopiclone.
PrilocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Eszopiclone is combined with PSD502.
PyrimethamineThe metabolism of Eszopiclone can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Quetiapine.
QuinineThe metabolism of Eszopiclone can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Eszopiclone can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ramelteon.
RanolazineThe metabolism of Eszopiclone can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Eszopiclone.
RifabutinThe metabolism of Eszopiclone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Eszopiclone can be increased when combined with Rifampicin.
RifapentineThe metabolism of Eszopiclone can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Risperidone.
RitonavirThe metabolism of Eszopiclone can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Romifidine.
RopiniroleEszopiclone may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Eszopiclone.
RosiglitazoneThe metabolism of Eszopiclone can be decreased when combined with Rosiglitazone.
RotigotineEszopiclone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Eszopiclone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Eszopiclone is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Eszopiclone can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Secobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sevoflurane.
SildenafilThe metabolism of Eszopiclone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Eszopiclone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Eszopiclone can be increased when it is combined with Simeprevir.
Sodium oxybateEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Eszopiclone.
SorafenibThe metabolism of Eszopiclone can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Eszopiclone can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sufentanil.
SulfadiazineThe metabolism of Eszopiclone can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Eszopiclone can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Eszopiclone can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Eszopiclone.
SuvorexantThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Suvorexant.
TamoxifenThe metabolism of Eszopiclone can be decreased when combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tasimelteon.
TelaprevirThe metabolism of Eszopiclone can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Eszopiclone can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Eszopiclone.
TeriflunomideThe metabolism of Eszopiclone can be decreased when combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetrodotoxin.
ThalidomideEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Eszopiclone.
ThiamylalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tiagabine.
TicagrelorThe metabolism of Eszopiclone can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Eszopiclone can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tizanidine.
TocilizumabThe serum concentration of Eszopiclone can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Eszopiclone can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Eszopiclone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triflupromazine.
TrimethoprimThe metabolism of Eszopiclone can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Eszopiclone.
ValsartanThe metabolism of Eszopiclone can be decreased when combined with Valsartan.
VenlafaxineThe metabolism of Eszopiclone can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Eszopiclone can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Vilazodone.
VoriconazoleThe metabolism of Eszopiclone can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Xylazine.
ZafirlukastThe metabolism of Eszopiclone can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zimelidine.
ZiprasidoneThe metabolism of Eszopiclone can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Nutt DJ, Stahl SM: Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010 Nov;24(11):1601-12. doi: 10.1177/0269881109106927. Epub 2009 Nov 26. [PubMed:19942638 ]
  2. Hanson SM, Morlock EV, Satyshur KA, Czajkowski C: Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different. J Med Chem. 2008 Nov 27;51(22):7243-52. doi: 10.1021/jm800889m. [PubMed:18973287 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Nutt DJ, Stahl SM: Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010 Nov;24(11):1601-12. doi: 10.1177/0269881109106927. Epub 2009 Nov 26. [PubMed:19942638 ]
  2. Hanson SM, Morlock EV, Satyshur KA, Czajkowski C: Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different. J Med Chem. 2008 Nov 27;51(22):7243-52. doi: 10.1021/jm800889m. [PubMed:18973287 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Nutt DJ, Stahl SM: Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010 Nov;24(11):1601-12. doi: 10.1177/0269881109106927. Epub 2009 Nov 26. [PubMed:19942638 ]
  2. Hanson SM, Morlock EV, Satyshur KA, Czajkowski C: Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different. J Med Chem. 2008 Nov 27;51(22):7243-52. doi: 10.1021/jm800889m. [PubMed:18973287 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Nutt DJ, Stahl SM: Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010 Nov;24(11):1601-12. doi: 10.1177/0269881109106927. Epub 2009 Nov 26. [PubMed:19942638 ]
  2. Hanson SM, Morlock EV, Satyshur KA, Czajkowski C: Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different. J Med Chem. 2008 Nov 27;51(22):7243-52. doi: 10.1021/jm800889m. [PubMed:18973287 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Becker PM, Sattar M: Treatment of sleep dysfunction and psychiatric disorders. Curr Treat Options Neurol. 2009 Sep;11(5):349-57. [PubMed:19744401 ]
  4. Jufe GS: [New hypnotics: perspectives from sleep physiology]. Vertex. 2007 Jul-Aug;18(74):294-9. [PubMed:18265473 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23